- €227.04m
- €376.77m
- €201.57m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 59.05 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.78 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.13 | ||
| EV to EBITDA | 11.59 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -0.17% | ||
| Return on Equity | -9.72% | ||
| Operating Margin | -0.44% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 14.84 | 31.4 | 121.01 | 158.37 | 201.57 | 222.13 | 240.19 | 94.22% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +421.74 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Atrys Health SA, formerly Europath Biosciences SL, is Spain-based company primarily engaged in the predictive and personalized oncology therapies. It operates under Atrys brand name. Atrys is a clinical and translational research laboratory dedicated to the diagnosis, prognosis and treatment of cancer, including hematologic and solid malignancies. It has four areas of activity: Laboratory, Telemedicine, Radiotherapy, as well as Research and Development (R&D). The Company has its diagnostic laboratories and translational research in Barcelona and Granada, and offices in Madrid, Spain.
Directors
- Santiago de Torres Sanahuja CHM
- Isabel Lozano Fernandez CEO
- Jose Maria Huch Ginesta CFO
- Carlos Cordon-Cardo CSO
- Carlo Greco VPR
- Anna Colomer Valero OTH
- Victor Gonzalez Rumayor OTH
- Eduardo Mundt Dussel OTH
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 4th, 2007
- Public Since
- July 22nd, 2016
- No. of Employees
- 2,062
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
Madrid Stock Exchange- Shares in Issue
- 75,934,310
- Address
- C/ Principe de Vergara 132, 1 piso, MADRID, 28002
- Web
- https://www.atryshealth.com/es/
- Phone
- +34 934581561
- Auditors
- KPMG Auditores, SL
Upcoming Events for ATRY
Similar to ATRY
Clinica Baviera SA
Madrid Stock Exchange
Euroespes SA
Madrid Stock Exchange
FAQ
As of Today at 19:03 UTC, shares in Atrys Health SA are trading at €2.99. This share price information is delayed by 15 minutes.
Shares in Atrys Health SA last closed at €2.99 and the price had moved by -42.28% over the past 365 days. In terms of relative price strength the Atrys Health SA share price has underperformed the FTSE Global All Cap Index by -46.76% over the past year.
The overall consensus recommendation for Atrys Health SA is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Atrys Health SA does not currently pay a dividend.
Atrys Health SA does not currently pay a dividend.
Atrys Health SA does not currently pay a dividend.
To buy shares in Atrys Health SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €2.99, shares in Atrys Health SA had a market capitalisation of €227.04m.
Here are the trading details for Atrys Health SA:
- Country of listing: Spain
- Exchange: MCE
- Ticker Symbol: ATRY
Based on an overall assessment of its quality, value and momentum Atrys Health SA is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Atrys Health SA is €6.50. That is 117.39% above the last closing price of €2.99.
Analysts covering Atrys Health SA currently have a consensus Earnings Per Share (EPS) forecast of €0.02 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Atrys Health SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -29.71%.
As of the last closing price of €2.99, shares in Atrys Health SA were trading -23.72% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Atrys Health SA PE ratio based on its reported earnings over the past 12 months is 59.05. The shares last closed at €2.99.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Atrys Health SA's management team is headed by:
- Santiago de Torres Sanahuja - CHM
- Isabel Lozano Fernandez - CEO
- Jose Maria Huch Ginesta - CFO
- Carlos Cordon-Cardo - CSO
- Carlo Greco - VPR
- Anna Colomer Valero - OTH
- Victor Gonzalez Rumayor - OTH
- Eduardo Mundt Dussel - OTH